Targeted treatment for langerhans cell histiocytosis
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial is testing a new targeted pill (luvometinib) alone or with another drug (cytarabine) for people with Langerhans cell histiocytosis that needs whole-body treatment. The goal is to see if the new approach can shrink or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Langerhans cell histiocytosis (LCH).
- You must be at least 10 years old.
- Your doctor must have said you need treatment that affects your whole body.
- You must have at least one area of disease that can be seen on a PET scan.
- You should be generally well enough to be up and about (performance status 0-2 or Lansky score 60 or higher).
- You must not have other active cancers, serious eye problems, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.